ALK and non-small cell lung carcinoma: For example, EML4 is the most frequent fusion partner for ALK, but it is very rarely translocated with RET, ROS1 or NTRK1; likewise, CCDC6-RET and CD74-ROS1 fusions are frequently found in NSCLC patients, but CCDC6 fusion with ALK or ROS1 and CD74 fusion with ALK have never been described29,37–39 (Supplementary Fig. 10d–g).